These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 7026250)

  • 61. Clinical and haemodynamic responses to captopril and hydralazine in chronic congestive heart failure: the importance of preload reduction.
    Fitzgerald DJ; O'Callaghan WG; O'Malley K; Horgan J; O'Brien E
    Br J Clin Pharmacol; 1982; 14 Suppl 2(Suppl 2):217S-222S. PubMed ID: 6753903
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Hemodynamic interference of alprenolol with dihydralazine in normal and hypertensive man.
    Sannerstedt R; Stenberg J; Johnsson G; Werkö L
    Am J Cardiol; 1971 Sep; 28(3):316-20. PubMed ID: 5155758
    [No Abstract]   [Full Text] [Related]  

  • 63. Hemodynamic effects of sublingual nifedipine in congestive heart failure.
    Matsui S; Murakami E; Takekoshi N; Hiramaru Y; Murakami H; Kitano E; Masuya K; Saga T; Nomura M; Fujita S; Tsuji S
    Jpn Circ J; 1979 Dec; 43(12):1081-8. PubMed ID: 541827
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Hemodynamic evaluation of hydralazine dosage in refractory heart failure.
    Packer M; Meller J; Medina N; Gorlin R; Herman MV
    Clin Pharmacol Ther; 1980 Mar; 27(3):337-46. PubMed ID: 7357790
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Cardiocirculatory effects of nitrates in the treatment of clinical congestive heart failure.
    Mason DT; Awan NA; DeMaria AN; Lee G; Amsterdam EA
    Herz; 1978 Dec; 63(36):387-98. PubMed ID: 400159
    [No Abstract]   [Full Text] [Related]  

  • 66. Effects of captopril in heart failure complicating acute myocardial infarction and persistence of acute haemodynamic effects in chronic heart failure after 3 years of treatment.
    Mattioli G; Ricci S; Rigo R; Fusaro MT; Cappello C
    Postgrad Med J; 1986; 62 Suppl 1():164-6. PubMed ID: 3534855
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Hemodynamic effects of intravenous hydralazine in pregnant women with severe hypertension.
    Kuzniar J; Skret A; Piela A; Szmigiel Z; Zaczek T
    Obstet Gynecol; 1985 Oct; 66(4):453-8. PubMed ID: 4047535
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Arterial oxygenation and arterial oxygen transport in chronic myocardial failure at rest, during exercise and after hydralazine treatment.
    Rubin SA; Brown HV; Swan HJ
    Circulation; 1982 Jul; 66(1):143-8. PubMed ID: 7083500
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Beneficial effects of hydralazine on rest and exercise hemodynamics in patients with chronic severe aortic insufficiency.
    Greenberg BH; DeMots H; Murphy E; Rahimtoola S
    Circulation; 1980 Jul; 62(1):49-55. PubMed ID: 7379285
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Cardiovascular alterations in severe pregnancy-induced hypertension seen with an intravenously given hydralazine bolus.
    Cotton DB; Gonik B; Dorman KF
    Surg Gynecol Obstet; 1985 Sep; 161(3):240-4. PubMed ID: 4035539
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The effects of oral hydralazine on blood pressure, cardiac output and peripheral resistance with respect to dose, age and acetylator status.
    Rowell NP; Clark K
    Radiother Oncol; 1990 Aug; 18(4):293-8. PubMed ID: 2244017
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Adverse effect of hydralazine in patients with primary pulmonary hypertension.
    Kronzon I; Cohen M; Winer HE
    JAMA; 1982 Jun; 247(22):3112-4. PubMed ID: 7077805
    [No Abstract]   [Full Text] [Related]  

  • 73. Hemodynamic effects of hydralazine in infants with idiopathic dilated cardiomyopathy and congestive heart failure.
    Artman M; Parrish MD; Appleton S; Boucek RJ; Graham TP
    Am Heart J; 1987 Jan; 113(1):144-50. PubMed ID: 3799428
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Indoramin in heart failure: possible adverse effects on hemodynamics and exercise capacity.
    Seth L; Galiè N; Casebolt P; Gimenez H; Malloy M; Franciosa JA
    Clin Pharmacol Ther; 1986 Nov; 40(5):567-74. PubMed ID: 3769387
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Drug therapy. Hydralazine.
    Koch-Weser J
    N Engl J Med; 1976 Aug; 295(6):320-3. PubMed ID: 778618
    [No Abstract]   [Full Text] [Related]  

  • 76. Dose requirements of hydralazine in patients with severe chronic congestive heart failure.
    Packer M; Meller J; Medina N; Gorlin R; Herman MV
    Am J Cardiol; 1980 Mar; 45(3):655-60. PubMed ID: 7355762
    [No Abstract]   [Full Text] [Related]  

  • 77. Dose-related hemodynamic and renal effects of dopamine in congestive heart failure.
    Beregovich J; Bianchi C; Rubler S; Lomnitz E; Cagin N; Levitt B
    Am Heart J; 1974 May; 87(5):550-7. PubMed ID: 4818699
    [No Abstract]   [Full Text] [Related]  

  • 78. 5-HT2-receptor blockade in the treatment of heart failure. A preliminary study.
    Demoulin JC; Bertholet M; Soumagne D; David JL; Kulbertus HE
    Lancet; 1981 May; 1(8231):1186-8. PubMed ID: 6112531
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Reassessment of the effects of vasodilator drugs in primary pulmonary hypertension: guidelines for determining a pulmonary vasodilator response.
    Rich S; Martinez J; Lam W; Levy PS; Rosen KM
    Am Heart J; 1983 Jan; 105(1):119-27. PubMed ID: 6849224
    [No Abstract]   [Full Text] [Related]  

  • 80. Hemodynamic effects of hydralazine in infants with a large ventricular septal defect.
    Beekman RH; Rocchini AP; Rosenthal A
    Circulation; 1982 Mar; 65(3):523-8. PubMed ID: 6459891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.